Topic: vaccine development
Pfizer is counting on some later-stage shots to carry the torch after its blockbuster Prevnar slows down. But it's stocking its early pipeline, too.
The International AIDS Vaccine Initiative will use grant funding to develop a Lassa vaccine based on the VSV vector.
VBI-1501 showed neutralizing antibody activities against both fibroblast and epithelial cell infections.
Pfizer has three vaccine programs in development—and top executives have high hopes—but two key programs have competitors close behind.
Bill Gates and Larry Page set up a challenge to develop a universal flu shot.
A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.
The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.
The FDA is evaluating the possibility of prosecuting those involved in rogue herpes vaccine research led by a Southern Illinois University professor.
The five-year grant will support Inovio through phase 2 development of DNA vaccines against Lassa fever and MERS.
Experts say technology is advancing to develop vaccines faster at a time of increasing emerging disease outbreaks.